Identity
Pinealon is a synthetic tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to Vladimir Khavinson's class of peptide bioregulators — ultrashort peptides of two to seven residues proposed to act as endogenous, tissue-specific regulators of gene expression. Within that framework, compounds are grouped as cytomedins (extracted from tissue) or cytogens (synthetic); Pinealon is a cytogen, described as the synthetic equivalent of an active fragment associated with pineal and neural tissue.
Its proposed target tissue is the central nervous system, which distinguishes it from its better-known relatives: epitalon (AEDG, aimed at pineal/telomerase biology) and epithalamin (the undefined bovine pineal extract from which the programme originated). All three come from the same institute and the same theoretical framework, and all three are routinely discussed as if evidence for one supports the others. They are different molecules with separate — and in every case single-source — evidence.
Development & history
- 1970s onward: The St Petersburg Institute of Bioregulation and Gerontology, under Khavinson, develops the peptide bioregulator framework, beginning with tissue extracts (cytomedins) and moving to defined synthetic short peptides (cytogens).
- 2000s: Pinealon (EDR) emerges as the CNS-directed member of the family. Work focuses on antioxidant and anti-apoptotic effects in neuronal cultures, particularly rat cerebellar granule cells under oxidative and hypoxic stress.
- 2012: Arutjunyan and colleagues report that maternal Pinealon administration protects rat offspring against neurodevelopmental damage from prenatal hyperhomocysteinaemia, with reduced ROS accumulation and fewer necrotic brain cells (Int J Clin Exp Med).
- 2014-2015: Mendzheritskiĭ, Karantysh, Ryzhak and colleagues examine Pinealon in combination with Cortexin, reporting effects on serum cytokines, brain caspase-3 activity, and behaviour.
- Mechanistic strand: Fedoreyeva, Kireev, Khavinson and Vanyushin publish work on nuclear penetration of fluorescence-labelled short peptides in HeLa cells and in vitro binding of such peptides to deoxyribooligonucleotides and DNA — the foundation of the peptide-DNA interaction hypothesis.
- 2024: Kraskovskaya, Linkova, Sakhenberg and colleagues report that short peptides including EDR protect fibroblast-derived induced neurons from age-related changes (Int J Mol Sci) — the most recent primary experimental citation identified.
- To date: no human trial, and no study identified from a group unaffiliated with the originating network.
Mechanism (as proposed)
The proposed mechanism has two parts. The downstream part is conventional and unremarkable: antioxidant activity, reduced ROS accumulation, suppression of apoptosis, and signalling through the MAPK/ERK cascade in neurons — effects reported in cerebellar granule cultures and stressed rodents.
The upstream part is the distinctive and contentious claim. The bioregulator framework holds that ultrashort peptides enter the cell nucleus and bind sequence-specifically to the major groove of DNA at promoter regions, thereby modulating transcription of tissue-specific genes — with the tissue specificity determined by cognate binding motifs, EDR mapping to neural tissue and AEDG to pineal and retinal tissue. Supporting evidence consists of nuclear-penetration imaging with labelled peptides and in vitro oligonucleotide binding assays.
This claim deserves to be stated with its difficulty visible. Sequence-specific DNA recognition is normally achieved by structured protein domains substantially larger than three amino acids; a tripeptide has very little information content with which to specify a genomic address. That does not make the observation impossible, but it does mean the burden of proof is high, the supporting work is in vitro and from the originating group, and independent confirmation of tissue-specific transcriptional regulation by EDR was not identified.
Reading the evidence honestly
Three things, in order.
No human data exist, and the product is sold for human use. Pinealon is marketed in capsule form as a brain bioregulator for cognition, sleep and neuroprotection. There is no human efficacy trial, no human pharmacokinetic study and no human safety dataset. The entire evidence base is cells and rodents. This gap is not unusual in the research-peptide market, but it is unusually stark here because the product is packaged and sold as a consumer supplement rather than as a research chemical.
The evidence is single-network and largely inaccessible. Every primary study identified traces to the Khavinson programme or its collaborators, and much of the wider bioregulator literature is published in Russian without translation. Beyond that, Pinealon has attracted almost no independent scientific attention — most of what is written about it comes from vendors. When the main information sources are the sellers, the ordinary checks of scientific publication are absent.
Two design details cut against the strongest claims. Most neuroprotection work used pretreatment — dosing before the injury — which is much easier to demonstrate than post-injury rescue and has little clinical analogue. And several of the behavioural studies used Pinealon together with Cortexin, meaning any behavioural benefit belongs to the combination, not to Pinealon alone. Neither point is hidden in the source papers; both tend to disappear in the summaries built on them.
The grade reflects a defined, plausible-enough small peptide with directionally consistent preclinical signals, an extraordinary and under-evidenced mechanistic claim, no independent replication, and no human data at all.